Cited by 472Pharmacogenetics and Drug MetabolismDrug Transport and Resistance MechanismsMetal-Catalyzed Oxygenation Mechanisms

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7

Williams, J.Andrew, Ring, Barbara J., Cantrell, Varon E., Jones, David R., Eckstein, James, Ruterbories, Kenneth, Hamman, Mitchell A., Hall, Stephen D., Wrighton, Steven A.·2002·Drug Metabolism and Disposition

DOI 10.1124/dmd.30.8.883

Open this paper in CoChat — free account

Abstract

The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5 contributes more significantly to the total liver CYP3A than was originally thought. CYP3A7 is the major fetal form and is rarely expressed in adults. To compare the metabolic capabilities of CYP3A forms for 10 substrates, incubations were performed using a consistent molar ratio (1:7:9) of recombinant CYP3A, P450 reductase, and cytochrome b5. A wide range of substrate concentrations was examined to determine the best fit to kinetic models for metabolite formation. In general, K(m) or S(50) values for the substrates were 3 to 4 times lower for CYP3A4 than for CYP3A5 or CYP3A7. For a more direct comparison of these P450 forms, clearance to the metabolites was determined as a linear relationship of rate of metabolite formation for the lowest substrate concentrations examined. The clearance for 1'-hydroxy midazolam formation at low substrate concentrations was similar for CYP3A4 and CYP3A5. For CYP3A5 versus CYP3A4, clearance values at low substrate concentrations were 2 to 20 times lower for the other biotransformations. The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 - CYP3A7). The CYP3A forms demonstrated regioselective differences in some of the biotransformations. These results demonstrate an equal or reduced metabolic capability for CYP3A5 compared with CYP3A4 and a significantly lower capability for CYP3A7.

Integrity signals

Registry

Crossref · 10.1124/dmd.30.8.883

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,978
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L. M. H., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,946
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
Kuehl, P. M., Zhang, J., Lin, Y., Lamba, J. K., Assem, M., Schuetz, J. D., Watkins, P. B., Daly, A. K., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,172
Self-citation
Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites
Korzekwa, K., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J., & Tracy, T. S. (1998) · Biochemistry · doi:10.1021/bi9715627 · Cited by 507
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Wrighton, S. A., Brian, W., Sari, M., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., & VandenBranden, M. R. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09441-6 · Cited by 399
Self-citation
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Self-citation
In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
Houston, J. B., & Kenworthy, K. E. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15358-5 · Cited by 391
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 334
Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates
Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C. L., Dandeneau, A. A., Miller, V. P., & Crespi, C. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13672-0 · Cited by 271
Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
Schuetz, J. D., Beach, D. L., & Guzelian, P. S. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00002 · Cited by 269

Show all 32 references

Research works printed but not linked: 2

Benet LZ (1996) Pharmacokinetics Goodman and Gilman's: The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG ed) pp 14 McGraw-Hill, New York.
Copeland RA (1996) Enzyme Kinetics. Wiley-VCH Inc., New York.

Sorted by citations

Items 201–300 of 472

Apparent High CYP3A5 Expression Is Required for Significant Metabolism of Vincristine by Human Cryopreserved Hepatocytes
Dennison, J. B., Mohutsky, M. A., Barbuch, R. J., Wrighton, S. A., & Hall, S. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139998 · Cited by 33
Self-citation
The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals
Lee, S., Lee, S. S., Jeong, H., Shon, J., Ryu, J.-Y., Sunwoo, Y. E., Liu, K., Kang, W., Park, Y.-J., Shin, C.-M., et al. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016733 · Cited by 33
Frequencies of CYP3A5 genotypes and haplotypes in a Korean population
Park, S. Y., Kang, Y. S., Jeong, M. S., Yoon, H. K., & Han, K. O. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00879.x · Cited by 32
Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies
Yoshida, S., Honjo, T., Iino, K., Ishibe, R., Leo, S., Shimada, T., Watanabe, T., Ishikawa, M., Maeda, K., Kusuhara, H., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.12.017 · Cited by 32
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
Kaehler, M., & Cascorbi, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.696960 · Cited by 34
The impact ofCYP3A5*3polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically‐based pharmacokinetic model
Emoto, C., Fukuda, T., Venkatasubramanian, R., & Vinks, A. A. T. M. M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12743 · Cited by 32
Evaluation of Calibration Curve–Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes
Zhang, G., Ho, T., Callendrello, A. L., Clark, R. J., Santone, E. A., Kinsman, S., Xiao, D., Fox, L. G., Einolf, H. J., & Stresser, D. M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058602 · Cited by 31
Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology
Abe, S., Kobayashi, K., Oji, A., Sakuma, T., Kazuki, K., Takehara, S., Nakamura, K., Okada, A., Tsukazaki, Y., Senda, N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15033-0 · Cited by 31
The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
van Groen, B. D., Krekels, E. H. J., Mooij, M. G., van Duijn, E., Vaes, W. H. J., Windhorst, A. D., van Rosmalen, J., Hartman, S. J. F., Hendrikse, N. H., Koch, B. C. P., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1890 · Cited by 31
Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer
Subhani, S., & Jamil, K. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.05.018 · Cited by 31
CYP Isoforms Involved in the Metabolism of Clarithromycin in vitro: Comparison between the Identification from Disappearance Rate and that from Formation Rate of Metabolites
Suzuki, A., Iida, I., Hirota, M., Akimoto, M., Higuchi, S., Suwa, T., Tani, M., Ishizaki, T., & Chiba, K. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.104 · Cited by 31
Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes
Patki, K. C., Moltke, L. L., Harmatz, J. S., Hesse, L. M., Court, M. H., & Greenblatt, D. J. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.059311 · Cited by 31
Inter-individual variation in midazolam clearance in children
Altamimi, M., Sammons, H. M., & Choonara, I. (2014) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-305720 · Cited by 30
Developmental regulation of kidney and liver solute carrier and ATP-binding cassette drug transporters and drug metabolizing enzymes: the role of remote organ communication
Momper, J. D., & Nigám, S. K. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1473376 · Cited by 30
Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence
Butranova, O. I., Ushkalova, E. A., Zyryanov, S. K., Станиславович, Ч. М., & Александровна, Б. Е. (2023) · Biomedicines · doi:10.3390/biomedicines11061633 · Cited by 30
Gene expression in primate liver during viral hemorrhagic fever
Djavani, M. M., Crasta, O. R., Zhang, Y., Zapata, J. C., Sobral, B., Lechner, M. G., Bryant, J., Davis, H., & Salvato, M. S. (2009) · Virology Journal · doi:10.1186/1743-422x-6-20 · Cited by 30
Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients
Miura, M., Inoue, K., Kagaya, H., Satoh, S., Tada, H., SAGAE, Y., Habuchi, T., & Suzuki, T. (2007) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.544 · Cited by 30
Effects of NO-1886 (Ibrolipim), a Lipoprotein Lipase-Promoting Agent, on Gene Induction of Cytochrome P450s, Carboxylesterases, and Sulfotransferases in Primary Cultures of Human Hepatocytes
Nishimura, M., Imai, T., Morioka, Y., Kuribayashi, S., Kamataki, T., & Naito, S. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.422 · Cited by 30
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity
Zhai, Q., van der Lee, M., van Gelder, T., & Swen, J. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.912618 · Cited by 29
Contribution of CYP3A Isoforms to Dealkylation of PDE5 Inhibitors: A Comparison between Sildenafil N-Demethylation and Tadalafil Demethylenation
Takahiro, R., Nakamura, S., Kohno, H., Yoshimura, N., Nakamura, T., Ozawa, S. W., Hirono, K., Ichida, F., & Taguchi, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00566 · Cited by 29
Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
Kovar, L., Weber, A., Zemlin, M., Kohl, Y., Bals, R., Meibohm, B., Selzer, D., & Lehr, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100908 · Cited by 28
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review
Iuliis, F. D., Salerno, G., Taglieri, L., & Scarpa, S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2818-4 · Cited by 28
A Semi‐Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics
Quinney, S. K., Mohamed, A., Hébert, M. F., Haas, D. M., Clark, S., Umans, J., Caritis, S. N., & Li, L. (2012) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.5 · Cited by 28
Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First‐Pass CYP3A Activity
Kharasch, E. D., Walker, A., Hoffer, C. J., & Sheffels, P. R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280077 · Cited by 28
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration
Hole, K., Gjestad, C., Heitmann, K., Haslemo, T., Molden, E., & Bremer, S. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2178-y · Cited by 27
Intrauterine growth restriction alters the activity of drug metabolising enzymes in the maternal-placental-fetal unit
McBride, G. M., Meakin, A. S., Soo, J. Y., Darby, J. R. T., Varcoe, T. J., Bradshaw, E. L., Lock, M. C., Holman, S. L., Saini, B. S., Macgowan, C. K., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120016 · Cited by 26
New treatment strategies for hepatitis C infection
Ermış, F. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i17.2100 · Cited by 26
Hepatic Stem Cells and Liver Development
Navarro–Álvarez, N., Soto–Gutiérrez, A., & Kobayashi, N. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-688-7_10 · Cited by 26
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy
Wang, D., & Sadée, W. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2040175 · Cited by 26
Predicting Maternal-Fetal Disposition of Fentanyl Following Intravenous and Epidural Administration Using Physiologically Based Pharmacokinetic Modeling
Shum, S., Shen, D. D., & Isoherranen, N. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000612 · Cited by 26
CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine
Kreutz, R. H., Bolbrinker, J., Beer, F. V. D. S.-D., Boeschoten, E. W., Dekker, F. W., Kain, S., Martus, P., Sietmann, A., Friedrichs, F., Stoll, M., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500488 · Cited by 26
In vivo effect of Schisandrin B on cytochrome P450 enzyme activity
Li, W.-L., Xin, H., Yu, A., & Wu, X. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.02.005 · Cited by 26
In Vitro Functionality of Human Fetal Liver Cells and Clonal Derivatives under Proliferative Conditions
Deurholt, T., ten Bloemendaal, L., Chhatta, A. A., van Wijk, A. C. W. A., Weijer, K. C., Seppen, J., Elferink, R. P. J. O., Chamuleau, R. A. F. M., & Hoekstra, R. (2006) · Cell Transplantation · doi:10.3727/000000006783464417 · Cited by 26
Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis
Şen, A., & Stark, H. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2846 · Cited by 25
Utility of DPX2 Cells for Predicting CYP3A Induction-Mediated Drug-Drug Interactions and Associated Structure-Activity Relationships
Fahmi, O. A., Raucy, J. L., Ponce, E., Hassanali, S., & Lasker, J. M. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047456 · Cited by 25
Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants
Butranova, O. I., Ushkalova, E. A., Zyryanov, S. K., & Станиславович, Ч. М. (2023) · Biomedicines · doi:10.3390/biomedicines11030940 · Cited by 24
A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic
Haas, D. M., Quinney, S. K., McCormick, C. L., Jones, D. R., & Renbarger, J. L. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.583700 · Cited by 24
Self-citation
Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response
Monroy‐Jaramillo, N., Fricke-Galindo, I., Ortega‐Vázquez, A., Cook, H. J., LLerena, A., & López, M. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0046 · Cited by 24
Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity
Krasulová, K., Holas, O., & Anzenbacher, P. (2017) · Molecules · doi:10.3390/molecules22111879 · Cited by 24
Polydopamine functionalized nanoporous graphene foam as nanoreactor for efficient electrode-driven metabolism of steroid hormones
Xu, X., Zheng, Q., Bai, G., Dai, Q., Cao, X., Yao, Y., Liu, S., & Yao, C. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.08.009 · Cited by 24
Expression and Regulation of Human Fetal-Specific CYP3A7 in Mice
Pang, X., Cheng, J., Kim, J. H., Matsubara, T., Krausz, K. W., & Gonzalez, F. J. (2012) · Endocrinology · doi:10.1210/en.2011-1020 · Cited by 23
Regulation of the CYP3A4 and CYP3A7 Promoters by Members of the Nuclear Factor I Transcription Factor Family
Riffel, A. K., Schuenemann, E., & Vyhlidal, C. A. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055699 · Cited by 23
Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism
Luo, X., Li, X., Hu, Z., & Cheng, Z. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.116 · Cited by 23
IMPACT OF TRANSCRIPTION FACTOR PROFILE AND CHROMATIN CONFORMATION ON HUMAN HEPATOCYTE CYP3A GENE EXPRESSION
Phillips, A., Hood, S. R., Gibson, G. G., & Plant, N. J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001461 · Cited by 23
Helices F-G are important for the Substrate specificities of CYP3A7
Torimoto, N., Ishii, I., Toyama, K.-I., Hata, M., Tanaka, K., Shimomura, H., Nakamura, H., Ariyoshi, N., Ohmori, S., & Kitada, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011304 · Cited by 22
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
Bartelink, I. H., van de Stadt, E. A., Leeuwerik, A. F., Thijssen, V. L., Hupsel, J., Nieuwendijk, J. D., Bahce, I., Yaqub, M. M., & Hendrikse, N. H. (2022) · Pharmaceuticals · doi:10.3390/ph15070796 · Cited by 22
Precision Dosing in Children
Hawcutt, D. B., Cooney, L., Oni, L., & Pirmohamed, M. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1138845 · Cited by 22
Inhibitory Effects of Continuous Ingestion of Schisandrin A on CYP3A in the Rat
Li, W., Xin, H., & Su, M. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00787.x · Cited by 22
Variability in Expression of CYP3A5 in Human Fetal Liver
Vyhlidal, C. A., Pearce, R. E., Gaedigk, R., Calamia, J. C., Shuster, D. L., Thummel, K. E., & Leeder, J. S. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064998 · Cited by 22
The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability
Qiu, H., Mathäs, M., Nestler, S., Bengel, C., Nem, D., Gödtel‐Armbrust, U., Lang, T., Taudien, S., Burk, O., & Wojnowski, L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328336bbeb · Cited by 22
Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling
Buyssens, L. A., Clerck, L. D., Schelstraete, W., Dhaenens, M., Deforce, D. L. D., Ayuso, M., Ginneken, C. J. V., & Cruchten, S. J. M. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665644 · Cited by 21
Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
Younes, S. N., Ismail, M. A., Al‐Jurf, R., Ziyada, A., Nasrallah, G. K., Abdulrouf, P. V., Nagy, M., Zayed, H., Farrell, T. J., Sorio, C., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2196866 · Cited by 21
Deletion of 30 Murine Cytochrome P450 Genes Results In Viable Mice With Compromised Drug Metabolism
Scheer, N., McLaughlin, L. A., Rode, A., MacLeod, A. K., Henderson, C. J., & Wolf, C. R. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057885 · Cited by 21
Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity
Chen, Y., Zhang, J., Zhu, P.-P., Xian-wen, T., Lin, Q.-H., Wang, W., Yin, S.-S., Gao, L.-Z., Su, M., Liu, C., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086637 · Cited by 21
Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5
Niwa, T., Narita, K., Okamoto, A., Murayama, N., & Yamazaki, H. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30558 · Cited by 21
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data
Neyshaburinezhad, N., Ghasim, H., Rouini, M. R., Daali, Y., & Ardakani, Y. H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080804 · Cited by 21
Investigation of ligand selectivity in CYP3A7 by molecular dynamics simulations
Fan, J., Zheng, Q., Cui, Y., Li, W.-K., & Zhang, H. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1054884 · Cited by 20
Comparison of CYP3A4 and CYP3A5: The Effects of Cytochrome b5 and NADPH-cytochrome P450 Reductase on Testosterone Hydroxylation Activities
Lee, S., & Goldstein, J. A. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-sh-030 · Cited by 20
Molecular Cloning, Expression, and Initial Characterization of Members of the CYP3A Family in Horses
Knych, H. K. D., McKemie, D. S., & Stanley, S. D. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032953 · Cited by 20
Different Enzyme Kinetics of Midazolam in Recombinant CYP3A4 Microsomes from Human and Insect Sources
Christensen, H., Mathiesen, L., Postvoll, L. W., Winther, B., & Molden, E. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.261 · Cited by 20
Contribution of Three CYP3A Isoforms to Metabolism of R- and S-Warfarin
Jones, D. R., Kim, S. Y., Boysen, G., Yun, C., & Miller, G. P. (2010) · Drug Metabolism Letters · doi:10.2174/187231210792928242 · Cited by 20
Self-citation
Limited contribution of CYP3A5 to the hepatic 6?-hydroxylation of testosterone
Kamdem, L. K., Meineke, I., Koch, I., Zanger, U. M., ller, J. R. B., & Wojnowski, L. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0944-3 · Cited by 20
Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers
Glue, P., Fang, A. F., Gandelman, K., & Klee, B. J. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000182358.63457.48 · Cited by 20
Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions
Lewis, D. F. V., Lake, B. G., Dickins, M., & Goldfarb, P. S. (2004) · Xenobiotica · doi:10.1080/00498250410001691325 · Cited by 20
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities
Dinh, J., Johnson, T. N., Grimstein, M., & Lewis, T. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112579 · Cited by 19
Development of a highly reproducible system to evaluate inhibition of cytochrome P450 3A4 activity by natural medicines
Sato, Y., Sasaki, T., Takahashi, S., Kumagai, T., & Nagata, K. (2015) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vk5g · Cited by 19
Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients
Sohn, M., Kim, M. G., Han, N., Kim, I.-W., Gim, J., Min, S., Song, E. Y., Kim, Y. S., Jung, H. S., Shin, Y. K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36085-w · Cited by 19
Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo
Johnson, T. N., Howgate, E. M., de Wildt, S. N., Turner, M. A., & Yeo, K. R. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001270 · Cited by 18
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects
Wennerholm, A., Allqvist, A., Svensson, J., Gustafsson, L. L., Mirghani, R. A., & Bertilsson, L. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0861-x · Cited by 18
In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study
Mai, H., Huang, J., Zhang, Y., Qu, N., Qu, H., Guo-Hui, M., Liu, J., Xu, X., & Chen, L. (2017) · Oncotarget · doi:10.18632/oncotarget.16465 · Cited by 18
Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations
Mutagonda, R. F., Minzi, O., Massawe, S. N., Asghar, M., Färnert, A., Kamuhabwa, A. A. R., & Aklillu, E. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088062 · Cited by 18
Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes
Takahashi, R., Forrest, W. F., Smith, A. D., Badée, J., Qiu, N., Schmidt, S., Collier, A. C., Parrott, N. J., & Fowler, S. M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000474 · Cited by 18
The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype
Shon, J., Ku, H.-Y., Bae, S.-Y., Oh, M., Yeo, C., Bae, S.-K., & Shin, J. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834b79e6 · Cited by 18
Pharmacogenetics and the Treatment of Chronic Myeloid Leukemia: How Relevant Clinically? An Update
Ankathil, R., Azlan, H., Abdullah, A. D., & Baba, A. A. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0193 · Cited by 18
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes
Tremmel, R., Hübschmann, D., Schaeffeler, E., Pirmann, S., Fröhling, S., & Schwab, M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001049 · Cited by 17
Characterization of kinetics of human cytochrome P 450s involved in bioactivation of flucloxacillin: inhibition of CYP 3 A ‐catalysed hydroxylation by sulfaphenazole
Dekker, S. J., Dohmen, F., Vermeulen, N. P. E., & Commandeur, J. N. M. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14548 · Cited by 17
Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment
Su, M., Chang, Y., Hernandez, D., Jones, R. J., & Ghiaur, G. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14298 · Cited by 17
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database
Adachi, K., Ohyama, K., Tanaka, Y., Sato, T., Murayama, N., Shimizu, M., Saito, Y., & Yamazaki, H. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100486 · Cited by 17
CYP2C8- and CYP3A-Mediated C-Demethylation of (3-{[(4-tert-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry-Nuclear Magnetic Resonance
Prakash, C., Wang, W., O’Connell, T. N., & Johnson, K. A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022897 · Cited by 16
Expression and enzyme activity of cytochrome P450 enzymes CYP 3A4 and CYP 3A5 in human skin and tissue‐engineered skin equivalents
Smith, S. A., Colley, H. E., Sharma, P., Slowik, K. M., Sison-Young, R. L. C., Sneddon, A., Webb, S. D., & Murdoch, C. (2017) · Experimental Dermatology · doi:10.1111/exd.13483 · Cited by 16
Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction
Jacobs, M. N., Kubíčková, B., & Boshoff, E. L. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.880818 · Cited by 17
Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil
Kharasch, E. D., Vangveravong, S., Buck, N. S., London, A. N., Kim, T., Blood, J., & Mach, R. H. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.313 · Cited by 16
State of Art of Dose Individualization to Support tacrolimus drug monitoring: What’s Next?
Lloberas, N., Fernández-Alarcón, B., Vidal‐Alabró, A., & Colom, H. (2025) · Transplant International · doi:10.3389/ti.2025.14201 · Cited by 15
Circulating Metabolite Abundances Associated With Risks of Bipolar Disorder, Schizophrenia, and Depression: A Mendelian Randomization Study
Lu, T., Chen, Y., Yoshiji, S., Ilboudo, Y., Forgetta, V., Zhou, S., & Greenwood, C. M. T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.04.016 · Cited by 15
CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity
Christensen, H., Hestad, A. L., Molden, E., & Mathiesen, L. (2010) · Xenobiotica · doi:10.3109/00498254.2010.523734 · Cited by 15
Discordant Associations Between SLCO1B1 521T→C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146
Zhang, X., Tierney, C., Albrecht, M., Demeter, L. M., Morse, G. D., DiFrancesco, R., Dykes, C., Jiang, H., & Haas, D. W. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318280d0ad · Cited by 15
Reevaluate In Vitro CYP3A Index Reactions of Benzodiazepines and Steroids between Humans and Dogs
Wu, Q., Hu, Y., Wang, C., Wei, W., Gui, L., Zeng, W., Liu, C., Jia, W. P., Miao, J., & Lan, K. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000864 · Cited by 15
A New CYP3A5 Variant, CYP3A5*11, Is Shown to Be Defective in Nifedipine Metabolism in a Recombinant cDNA Expression System
Lee, S., van der Heiden, I. P., Goldstein, J. A., & van Schaik, R. H. N. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012310 · Cited by 15
Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6
Xu, B. Q., Ishii, M., Ding, L. R., Fischer, N. E., & Inaba, T. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00093-6 · Cited by 15
CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites
Sood, D., Johnson, N., Jain, P., Siskos, A., Bennett, M. H., Gilham, C., Busana, M. C., Peto, J., dos‐Santos‐Silva, I., Keun, H. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.432 · Cited by 14
Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study
Small, D. S., Ferguson‐Sells, L. R., Dahdah, N., Bonnet, D., Landry, J., & Li, B. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14039 · Cited by 14
The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes
Zhou, Q., Matsumoto, S., Ding, L. R., Fischer, N. E., & Inaba, T. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.032 · Cited by 14
Does poor fetal growth influence the extent of fetal exposure to maternal medications?
Soo, J. Y., Wiese, M. D., Berry, M. J., & Morrison, J. L. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.001 · Cited by 14
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template
Yamazoe, Y., & Tohkin, M. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.09.002 · Cited by 14
Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated WithCYP3A5*3Allele or a Change in Diet Composition
Lee, S., Jusko, W. J., Salaita, C. G., Calis, K. A., Jann, M. W., Spratlin, V. E., Goldstein, J. A., & Hon, Y. Y. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006287588 · Cited by 14
Synthesis, docking studies, and in silico ADMET predictions of some new derivatives of pyrimidine as potential KSP inhibitors
Rashid, U., Hassan, S. F., Nazir, S., Wadood, A., Waseem, M., & Ansari, F. L. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1120-z · Cited by 14
Cytochrome P450 Gene-Based Drug Prescribing and Factors Impacting Translation into Routine Clinical Practice
Wilke, R. A., Musana, K. A., & Weber, W. W. (2005) · Personalized Medicine · doi:10.2217/17410541.2.3.213 · Cited by 14
Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
Parvez, M. M., Thakur, A., Mehrotra, A., Stancil, S. L., Pearce, R. E., Basit, A., Leeder, J. S., & Prasad, B. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3354 · Cited by 13
Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7
Shum, S., & Isoherranen, N. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00537-x · Cited by 13
Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates
Kandel, S. E., & Lampe, J. N. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00028 · Cited by 13

Authors: Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A.
Affiliations: Eli Lilly (United States) (US)
ORCID: Hall, Stephen D.
Venue: Drug Metabolism and Disposition
Publisher: Elsevier BV
Published: 2002-08
Volume: 30
Issue: 8
Pages: 883-891
ISSN: 0090-9556 (ISSN-L)
DOI: 10.1124/dmd.30.8.883
OpenAlex: W2052406081
Cited by: 471
References: 32
Citations by year: 2026: 10 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 21 · 2021: 31 · 2020: 16 · 2019: 21 · 2018: 18 · 2017: 18 · 2016: 14 · 2015: 22 · 2014: 15 · 2013: 24 · 2012: 14
FWCI: 19.66
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Drug Metabolism and Disposition (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
Keywords: CYP3A4, CYP3A5, CYP3A7, cytochrome P450, drug metabolism, midazolam hydroxylation, clarithromycin, regioselectivity, enzyme kinetic parameters
MeSH terms: Alprazolam, Aryl Hydrocarbon Hydroxylases, Biotransformation, Coumarins, Cytochrome P-450 Enzyme System, Diltiazem, Estradiol, Humans, Kinetics, Microsomes, Liver, Midazolam, Nifedipine, Tamoxifen, Testosterone, Triazolam, Cytochromes b5, Clarithromycin, Cytochrome P-450 CYP3A, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks